-transparent.png){kind=logo}
Leukocyte migration inhibitory factor (LMIF) activity was tested before and after glucagon administration both in vivo and in vitro. In vivo glucagon 1 mg i.v. vs saline administration inhibited LMIF production by T lymphocytes in 85.21% patients (p less than 0.01). In vitro glucagon in physiologic (125 pg/ml) and pharmacologic (50 ng/ml) doses increased the migration area vs PPD 250 microL (migration index 0.5127 vs 0.3210; p less than 0.05). These results show a significant inhibitory effect of glucagon upon LMIF activity. We suggest that glucagon acts by enhancement of the intralymphocytic cAMP/cGMP ratio (cyclic adenosine monophosphate/cyclic guanosine monophosphate).
D Pereţianu, and
A Deleanu, and
V Lotreanu, and
A Mogoş, and
C Beşliu, and
D Tănase
April 1977,
Cellular immunology,
D Pereţianu, and
A Deleanu, and
V Lotreanu, and
A Mogoş, and
C Beşliu, and
D Tănase
September 1978,
Investigative ophthalmology & visual science,
D Pereţianu, and
A Deleanu, and
V Lotreanu, and
A Mogoş, and
C Beşliu, and
D Tănase
January 1981,
Archivum immunologiae et therapiae experimentalis,
D Pereţianu, and
A Deleanu, and
V Lotreanu, and
A Mogoş, and
C Beşliu, and
D Tănase
January 1981,
Laboratornoe delo,
D Pereţianu, and
A Deleanu, and
V Lotreanu, and
A Mogoş, and
C Beşliu, and
D Tănase
December 1975,
Acta allergologica,
D Pereţianu, and
A Deleanu, and
V Lotreanu, and
A Mogoş, and
C Beşliu, and
D Tănase
April 1974,
Journal of immunology (Baltimore, Md. : 1950),
D Pereţianu, and
A Deleanu, and
V Lotreanu, and
A Mogoş, and
C Beşliu, and
D Tănase
July 1979,
Immunopharmacology,
D Pereţianu, and
A Deleanu, and
V Lotreanu, and
A Mogoş, and
C Beşliu, and
D Tănase
April 1978,
Cellular immunology,
D Pereţianu, and
A Deleanu, and
V Lotreanu, and
A Mogoş, and
C Beşliu, and
D Tănase
January 1981,
Digestion,
D Pereţianu, and
A Deleanu, and
V Lotreanu, and
A Mogoş, and
C Beşliu, and
D Tănase
January 1991,
Revista alergia : organo oficial de la Sociedad Mexicana de Alergia e Inmunlogia,
